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Objectives. We sought to evaluate 1) the cost-effectiveness of
amiodarone therapy in postinfarction patients; and 2) the influ-
ence of alternative diagnostic strategies (noninvasive only vs.
noninvasive and electrophysiologic testing) on survival benefit
and cost-effectiveness ratio of amiodarone therapy.
Background. The cost-effectiveness of amiodarone therapy in
postinfarction patients is still unknown, and no study has deter-
mined which diagnostic strategy should be used to maximize
amiodarone survival benefit while improving its cost-effectiveness
ratio.
Methods. We designed a postinfarction scenario wherein heart
rate variability analysis on 24-h Holter monitoring was used as a
screening test for 2-year amiodarone therapy in a cohort of
survivors (mean age 57 years) of a recent myocardial infarction.
Three different therapeutic strategies were compared: 1) no
amiodarone; 2) amiodarone in patients with depressed heart rate
variability; 3) amiodarone in patients with depressed heart rate
variability and a positive programmed ventricular stimulation.
Total variable costs and quality-adjusted life expectancy during a
20-year period were predicted with use of a Markov simulation
model. Costs and charges were calculated with reference to an
Italian and American hospital.
Results. Amiodarone therapy in patients with depressed heart
rate variability and a positive programmed ventricular stimula-
tion was dominated by a blend of the two alternatives. Compared
with the no-treatment strategy, the incremental cost-effectiveness
ratio of amiodarone therapy in patients with depressed heart rate
variability was $10,633 and $39,422 per gained quality-adjusted
life-year using Italian costs and American charges, respectively.
Conclusions. Compared with a noninterventional option, ami-
odarone prescription in all patients with depressed heart rate
variability seems to be a more appropriate approach than the
alternative based on the combined use of heart rate variability and
electrophysiologic study.
(J Am Coll Cardiol 1998;31:1481–90)
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Prevention of malignant ventricular tachyarrhythmias remains
a major problem after acute myocardial infarction. At present,
only beta-adrenergic blocking agents have been shown (1) to
be effective for diminishing the incidence of sudden death after
myocardial infarction. Therefore, alternative and complemen-
tary therapeutic approaches are under investigation. Initial
trials with empiric low dose amiodarone treatment have been
promising (2–5). However, amiodarone therapy is an expensive
treatment; the incidence of serious side effects may be rela-
tively high; and a properly constructed program for long-term
follow-up, including methods for monitoring drug adverse
reactions on a regular basis, is necessary (6). Moreover, results
from the Canadian Amiodarone Myocardial Infarction Ar-
rhythmia (CAMIAT) (7) and European Myocardial Infarct
Amiodarone (EMIAT) trials (8) did not show that the drug
reduced total or cardiac mortality, although arrhythmic mor-
tality was reduced. These findings do not support a systematic
prophylactic use of amiodarone in postinfarction patients but
suggest a role for the drug in patients at high risk of arrhyth-
mias for whom amiodarone will offer a substantial benefit.
Nevertheless, the cost-effectiveness of low dose amiodarone
therapy in postinfarction patients is still unknown. Moreover,
no study has pointed out which diagnostic strategy should be
used to maximize the amiodarone survival benefit and improve
the cost-effectiveness ratio. With regard to risk assessment,
depressed heart rate variability was found to be associated with
cardiac mortality, particularly sudden death (9). However, our
group (10) and others (11) have reported that programmed
ventricular stimulation in patients preselected by noninvasive
techniques has an additional benefit for improving diagnostic
accuracy. Thus, the combined use of programmed ventricular
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stimulation and heart rate variability analysis could be more
cost-effective than a simple noninvasive approach. Because of
its higher specificity, the combined approach could reduce
false positive results and decrease the number of patients
needing amiodarone treatment during follow-up. Therefore,
the objectives of the present study were to evaluate: 1) the
cost-effectiveness of amiodarone therapy in postinfarction
patients at high risk of arrhythmic death; and 2) whether the
use of alternative diagnostic strategies (heart rate variability
assessment vs. heart rate variability and electrophysiologic
testing) may influence amiodarone survival benefit and cost-
effectiveness.
Methods
Study design. We constructed a Markov simulation model
(12) to compare three alternative diagnostic and therapeutic
strategies in three groups of postinfarction patients. A Markov
model assumes that a hypothetical cohort of patients moves
through a sequence of health states. Changes from one state to
another are determined by a set of transition probabilities that
are either time dependent or constant. We used DATA by
TreeAge software (13) to simulate the prognosis of each
cohort and “monitor” their progress at 1-year intervals for a
20-year period tracking relevant events, total survival time and
costs. To strengthen the results, both Italian and American
costs were introduced into the analysis.
Decision model. We designed a scenario in which heart
rate variability analysis on 24-h Holter monitoring was used as
a screening test for amiodarone therapy after myocardial
infarction. Our base-case analysis evaluated survivors of a
recent myocardial infarction (men in 79% of cases, mean age
57 years) free from contraindications to amiodarone, of whom
54% and 40% were treated with thrombolysis and beta-
blockers, respectively (9). As shown in Figure 1, three groups
of patients were considered: 1) In the first group, no amioda-
rone therapy was prescribed. 2) In the second group, all patients
with depressed heart rate variability were treated with amio-
darone during the first 2 years after myocardial infarction, after
receipt of an oral loading dose during an additional week in the
hospital and undergoing baseline tests to screen for potential
drug toxicity during follow-up. 3) In the third group, all patients
with depressed heart rate variability underwent programmed
ventricular stimulation, and only those with positive pro-
grammed stimulation, defined as the induction of sustained
monomorphic ventricular tachycardia of ,270 beats/min, re-
ceived amiodarone therapy.
Estimation of mortality. After hospital discharge, they were
entered into the Markov process, where for each 1-year period
they were exposed to three time-dependent forces of mortality:
1) arrhythmic cardiac mortality; 2) nonarrhythmic cardiac
mortality; 3) noncardiac mortality.
We estimated mortality rates during the first year and
constant mortality rates for each subsequent year up to year 10
and for years 11 to 20 (14). First-year cardiac mortality rates
and proportion of arrhythmic deaths were estimated from
published reports (9–11,15,16) and are shown in Table 1. To
obtain subsequent annual cardiac mortality rates for years 2 to
10, these estimates were patterned on data from other studies
(14,17–19) in which patients had a first-year mortality rate
similar to ours. The proportion of arrhythmic death was assumed
to be constant for years 1 to 10. The yearly noncardiac mortality
rate was 0.012 and maintained constant for years 1 to 10 (19).
Patients at very high risk who showed a first-year cardiac
mortality rate .0.11 were assumed to have a 0.075 annual
cardiac mortality rate for years 2 to 10. Patients with a
first-year cardiac mortality rate of 0.10 to 0.11 were defined as
being at high risk and were assumed to have a 0.065 subse-
quent annual cardiac mortality rate. Patients with a first-year
cardiac mortality rate of 0.07 to 0.08 were defined as being at
intermediate risk and were assumed to have a 0.05 annual
cardiac mortality rate in the following years. Patients with
negative results on noninvasive testing were defined as being at
low risk, with a first-year cardiac mortality rate of 0.015, and
were assumed to have a 0.015 annual cardiac mortality rate for
years 2 to 10. As shown in Table 1, by the sensitivity analysis,
the first-year cardiac mortality rate in the low-risk group
ranged from 0.016 to 0.032, on the basis of the scenario
analyzed. The annual cardiac mortality rate for subsequent
years was adjusted to maintain an unchanged life expectancy
for the no-amiodarone strategy and ranged from 0.016 to
0.024.
Ten years after myocardial infarction, the annual all-cause
mortality rate of the survivors was assumed to be 0.037,
identical to that of a cohort of the same age and gender
according to national life-tables (20).
According to data on treatment analysis of the CAMIAT
(7) and EMIAT (8) trials, we assumed that amiodarone
reduces arrhythmic cardiac mortality by 39%, increases non-
arrhythmic cardiac and noncardiac mortality by 3% and 18%,
respectively, in the first 2 years after myocardial infarction.
Patients receiving amiodarone therapy were seen routinely
according to structured follow-up protocols summarized in
Table 2; the monitoring schedule recommended by Wilson and
Podrid (6) was adopted in our model. Amiodarone use might
be discontinued because of poor compliance or occurrence of
nonfatal “drug-related” complications. The difference in the
adverse event rate between amiodarone and placebo was used
in the model according to data from the CAMIAT (7) and
EMIAT (8) trials.
Medical rates and probabilities used in the model were
based on published reports, as shown in Table 1 (7,8,10,11,14–
22).
Measurement of costs. As shown in Table 3, assumptions
used in the model were derived from costs calculated at the
Abbreviations and Acronyms
CAMIAT 5 Canadian Amiodarone Myocardial Infarction Arrhythmia
Trial
EMIAT 5 European Myocardial Infarct Amiodarone Trial
QALY 5 quality-adjusted life-year
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Tradate Rehabilitation Institute (Italy) and from actual
charges at Boston University Medical Center Hospital (Mas-
sachusetts). The Italian center is a small hospital size (130
beds), whereas the American center is a teaching and high cost
hospital. Costs and charges are shown in Table 3, expressed in
1994 U.S. dollars (1 U.S. dollar 5 1,586 Italian lire). Indirect
costs, such as patient time or production losses, are not
included.
A detailed micro-costing methodology was used to calculate
most costs at the Tradate Rehabilitation Institute. The costs of
diagnostic tests include staff time, supplies, equipment and
overhead. Treatment costs include costs of therapy (including
drug and testing during follow-up or monitoring and surveil-
lance of patients) and costs of treating side effects related to
long-term amiodarone toxicity. Italian costs are lower than
American costs because of lower prices, namely hourly wages,
and because they are production costs rather than charges to
third-party payers. Costs and charges of noninvasive tests were
not included in the model because they are common to all
alternatives in each scenario analyzed.
Quality of life adjustments. The best and worst quality of
life values were assigned to the “well” and “dead” states,
respectively. Patients remaining in the well state for 1 year
were credited with 1 quality-adjusted life-year (QALY). Pa-
tients who died no longer accrued QALYs. Short-term mor-
bidity was reflected by subtracting an amount of time from
total life expectancy. According to previous published esti-
mates (23,24), 2 and 3 weeks are deducted for execution of
electrophysiologic testing and drug side effects, respectively.
Figure 1. Decision model used for the cost-effectiveness analysis. The
initial choose node (square) leads to three management strategies.
Thus, three identical groups of postinfarction patients, with no con-
traindications to amiodarone therapy, undergo arrhythmic risk strati-
fication and, if necessary, amiodarone treatment. After hospital dis-
charge, they enter the Markov process to simulate prognosis over a
20-year period. The five nodes at right of the Markov node represent
the health states of the process, whose cycle length is assumed to be 1
year. The “Death” states are absorbing states; thus, no transition to
any other state is possible. Transitions are allowed for the other states,
and every terminal node represents a transition (i.e., a change in health
state). Everyone in the model is assumed to begin the process in the
“Well” state, which has initial probability of 1.0. In all groups, patients
may die according to transition probabilities that are time dependent
and influenced by both amiodarone therapy in the first 2 years and
results of risk stratification; otherwise, patients may survive. If they are
treated with amiodarone, they may discontinue the drug because of
poor compliance or occurrence of nonfatal “drug-related” adverse
reactions (Rxn), according to data from the CAMIAT (7) and EMIAT
(8) trials. HRV 5 heart rate variability; EPS 5 electrophysiologic
study; MI 5 myocardial infarction.
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Table 1. Probability Estimates and Sources Used in Study Model*
Input Variable Estimate Range Source (ref no.)
1st-yr P of cardiac death
HRV ,20 U 0.114 9
HRV $20 U 0.015 9
LVEF ,40% 0.072 9
LVEF $40% 0.027 9
PVCs/h .10 0.104 9
PVCs/h #10 0.029 9
Unsustained VT positive 0.081 9
Unsustained VT negative 0.035 9
SAECG positive 0.073 9
SAECG negative 0.032 9
LVEF and HRV 0.152 9
No LVEF and HRV 0.025 9
LVEF and PVCs 0.147 9
No LVEF and PVCs 0.031 9
LVEF and unsustained VT 0.132 9
No LVEF and unsustained VT 0.035 9
LVEF and SAECG 0.122 9
No LVEF and SAECG 0.034 9
EPS positive 0.125 0.239 10,11,15,16
EPS negative 0.105 0.055 10,11,15,16
Proportion of cardiac deaths classified as arrhythmic
HRV ,20 U 0.60 9
HRV $20 U 0.65 9
LVEF ,40% 0.50 9
LVEF $40% 0.78 9
PVCs/h .10 0.45 9
PVCs/h #10 0.72 9
Unsustained VT positive 0.67 9
Unsustained VT negative 0.60 9
SAECG positive 0.63 9
SAECG negative 0.59 9
LVEF and HRV 0.50 9
No LVEF and HRV 0.72 9
LVEF and PVCs 0.40 9
No LVEF and PVCs 0.71 9
LVEF and unsustained VT 0.55 9
No LVEF and unsustained VT 0.63 9
LVEF and SAECG 0.54 9
No LVEF and SAECG 0.65 9
EPS positive 0.80 0.77 10,11,15,16
EPS negative 0.51 0.27 10,11,15,16
1- to 10-yr P of noncardiac death 0.012 19
11- to 20-yr P of all-cause death 0.037 20
P of HRV ,20 U 0.25 9
P of LVEF ,40% 0.31 9
P of PVCs/h .10 0.17 9
P of unsustained VT positive 0.13 9
P of SAECG positive 0.23 9
P of LVEF and HRV 0.13 9
P of LVEF and PVCs 0.10 9
P of LVEF and unsustained VT 0.06 9
P of LVEF and SAECG 0.08 9
P of inducible sustained VT at EPS 0.24 10,11,15,16
Amiodarone variables
Change in arrhythmic death 20.39 20.33/20.45 7,8
Change in nonarrhythmic cardiac death 10.03 20.27/10.34 7,8
Change in noncardiac death 10.18 0/10.36 7,8
P of withdrawal (side effects or noncompliance) 0.034 7,8
P of severe adverse reactions 0.023 7,8
* Estimates were based on published studies but required modification for use as a model input. EPS 5
electrophysiologic study; HRV 5 heart rate variability; LVEF 5 left ventricular ejection fraction; P 5 probability;
PVCs 5 premature ventricular complexes; ref 5 reference; SAECG 5 signal-averaged electrocardiogram; VT 5
ventricular tachycardia.
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Life expectancy unadjusted for quality of life was also reported
(25).
Discounting. Future costs and benefits were discounted at
3% (reference case) and 5%/year (for comparison with past
analyses). Undiscounted results, which are often of interest,
were also reported (25).
Calculation of cost-effectiveness of alternative diagnostic
strategies. Quality-adjusted life expectancies of patients un-
der each regimen were combined with costs and charges to give
the total costs and effectiveness and incremental cost-
effectiveness ratios.
Sensitivity analysis. Sensitivity analyses were used to as-
sess whether variations in our estimates or assumptions signif-
icantly altered the results.
Results
Base-case analysis. The results of base-case analysis are
reported in Table 4. Using a discount rate of 3%, amiodarone
therapy, when given to all patients with depressed heart rate
variability, was the most expensive of the regimens but resulted
in the greatest quality-adjusted life expectancy. The strategy
based on amiodarone therapy in patients with low heart rate
variability and positive programmed ventricular stimulation
resulted in lower costs. However, compared with the no-
therapy option, the gain in life expectancy was small. Thus, the
strategy based on amiodarone therapy after combined use of
heart rate variability and electrophysiologic testing was domi-
nated by a blend of the two alternatives. Compared with the
no-treatment strategy, the incremental cost-effectiveness ratio
of amiodarone therapy according to heart rate variability
assessment was $10,633 and $39,422/QALY gained using Ital-
ian costs and American charges, respectively.
Data were reanalyzed using a discount rate of 5% for
comparison with past analyses, and undiscounted results were
also calculated. Discount rate did not affect the stability of the
results. Results unadjusted for quality of life were also re-
ported: Data showed that the results were insensitive to the
quality of life adjustment according to both Italian costs and
American charges.
Sensitivity analysis. Results of the sensitivity analysis are
reported in Figure 2. The output of the model for different
combinations of noninvasive testing was tested. The strategy
based on amiodarone after the combined use of noninvasive
testing and electrophysiologic study was dominated by a blend
of the two alternatives in five of the eight analyzed scenarios
for both Italian costs and American charges. Compared with
the no-therapy option, when amiodarone was given only to
patients with abnormal results on noninvasive testing, the
incremental cost-effectiveness ratios ranged from $16,275 to
$10,167 and from $60,350 to $37,767/QALY gained for Italian
costs and American charges, respectively. However, in three
scenarios, all based on the use of a single noninvasive test, no
strategy was clearly dominated by any other, and no strategy
Table 2. Protocol for Monitoring Amiodarone Side Effects
According to Wilson and Podrid (6) and the CAMIAT (7) and
EMIAT (8) Trials
Evaluation Examination Interval
Wilson and Podrid (6)
Blood chemistry, CBC Baseline and every 6 mo
Liver function tests Baseline and every 6 mo
Thyroid function tests Baseline and every 6 mo
Chest X-ray film Baseline and every 6 mo
Pulmonary function tests Baseline and for symptoms
Diffusing capacity for CO Baseline and for symptoms
Ophthalmologic examination Baseline and for symptoms
24-h Holter recording and analysis Baseline; at 1, 6 and 12 mo;
then every 6 mo
Follow-up visit Baseline; at 1, 6 and 12 mo;
then every 6 mo
CAMIAT (7)
Liver function tests Baseline and every 4 mo
Thyroid function tests Baseline and every 4 mo
Chest X-ray film Baseline; at 4, 12, 20 and
24 mo
24-h Holter recording and analysis Baseline; at 4, 8, 12, and
16 mo
Follow-up visit Baseline; at 2 wk; then every
4 mo
EMIAT (8)
Blood chemistry, CBC Baseline; at 2 wk; at 2 and
4 mo; then every 8 mo
Liver function tests Baseline; at 2 wk; at 2 and
4 mo; then every 8 mo
Thyroid function tests Baseline; at 2 wk; at 2 and
4 mo; then every 8 mo
Chest X-ray film Baseline; at 2, 12 and 24 mo
24-h Holter recording and analysis Baseline; at 2 wk; at 4 mo
Follow-up visit Baseline; at 2 wk; at 2 and
4 mo; then every 4 mo
CAMIAT 5 Canadian Amiodarone Myocardial Infarction Arrhythmia Trial.
CBC 5 complete blood count; CO 5 carbon monoxide; EMIAT 5 European
Myocardial Infarct Amiodarone Trial.
Table 3. Unit of Costs and Charges Used in the Model
Item
Unit Costs or Charges ($)
Tradate
Rehabilitation
Institute
Boston University
Medical Center
Hospital
24-h Holter recording and analysis 115 583
Programmed ventricular stimulation 682 3,477
12-lead ECG 19 110
Hospital stay (cost/day):
Hotel and treatment costs 186 835
Chest X-ray film 72 368
Thyroid function tests 70 103
Liver function tests and CBC 35 55
Ophthalmologic examination 108 230
Spirometry and flux-volume curve 112 334
Diffusing capacity for CO 176 359
Follow-up visit and 12-lead ECG 108 190
Amiodarone treatment (drugs/year) 105 105
Average cost of amiodarone toxicity 508 1,544
ECG 5 electrocardiogram; other abbreviations as in Table 2.
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was eliminated by extended dominance. Compared with the
no-treatment option, the strategy based on amiodarone given
to patients with abnormalities on both noninvasive testing and
electrophysiologic study had an incremental cost-effectiveness
ratio that ranged from $12,500 to $6,967 and from $53,650 to
$29,900/QALY gained for Italian costs and American charges,
respectively. The strategy based on amiodarone in all patients
with positive results on noninvasive testing further increased
quality-adjusted life expectancy, with an incremental cost-
effectiveness ratio that ranged from $35,050 to $17,400 and
from $115,000 to $57,133 for Italian costs and American
charges, respectively.
In the base-case analysis, mortality estimates for patients
evaluated with electrophysiologic study were based on a sen-
sitivity of programmed stimulation for cardiac arrhythmic and
nonarrhythmic death of 40% and 14%, respectively, and a
specificity of 77% (10,11,15,16). As shown in Figure 2, the
model was sensitive to an improvement in the diagnostic
accuracy of electrophysiologic testing, assuming a sensitivity of
programmed stimulation for cardiac arrhythmic and nonar-
rhythmic death of 78% and 20%, respectively, and a specificity
of 80% (10,11,16). Compared with the no-treatment option,
amiodarone after electrophysiologic study increased quality-
adjusted life expectancy, with an incremental cost-effectiveness
ratio of $4,900 and $21,150/QALY gained for Italian costs and
American charges, respectively. Amiodarone, when given to all
patients with depressed heart rate variability, further increased
quality-adjusted life expectancy, with an incremental cost-
effectiveness ratio of $56,500 and $185,600/QALY gained for
Italian costs and American charges, respectively.
Finally, we analyzed the sensitivity of the model to changes
in amiodarone effectiveness and follow-up design. As shown in
Figure 2, the results of the baseline analysis were confirmed in
three of the four tested alternative scenarios for both Italian
costs and American charges. Conversely, no strategy was
clearly dominated by any other, and no strategy was eliminated
by extended dominance when amiodarone effectiveness ob-
served in the EMIAT trial (8) was assumed in the model. The
incremental cost-effectiveness ratio of electrophysiologic
study-guided therapy was $19,950 and $85,800 for Italian costs
and American charges, respectively. Amiodarone, if given after
heart rate variability assessment only, further increased
quality-adjusted life expectancy, with an incremental cost-
effectiveness ratio of $27,600 and $90,600 using Italian costs
and American charges, respectively.
Discussion
On the basis of costs and charges from two centers, one in
Italy and the other in the United States, the present investiga-
tion provides an estimate of cost-effectiveness of amiodarone
therapy in postinfarction patients. The influence of alternative
diagnostic strategies (noninvasive only, based on heart rate
variability assessment, vs. the combined use of noninvasive and
electrophysiologic testing) on survival benefit and the cost-
effectiveness ratio of amiodarone therapy was also evaluated.
The combined use of electrophysiologic study and heart rate
variability assessment may significantly reduce total costs of
therapy, but the gain in quality-adjusted life expectancy due to
amiodarone is small. Therefore, compared with the no-therapy
option, amiodarone in patients at risk after heart rate variabil-
ity analysis seems to be a more cost-effective approach. More-
over, the cost-effectiveness ratio of amiodarone therapy in
postinfarction patients with depressed heart rate variability
Table 4. Base-Case Analysis for a 57-Year Old Postinfarction Patient, Showing Incremental Cost-Effectiveness Ratios
QALYs LYs
Tradate Rehabilitation Institute
Boston University Medical Center
Hospital
Cost
($)
Incremental C/E Ratio
Cost
($)
Incremental C/E Ratio
$ QALY $ LY $ QALY $ LY
QOL adjusted results
3% discount rate
No amiodarone 10.65
Amiodarone: HRV1EPS 10.68 399 ED 1,717 ED
Amiodarone: HRV 10.74 957 10,633 3,548 39,422
5% discount rate
No amiodarone 9.08
Amiodarone: HRV1EPS 9.10 397 ED 1,711 ED
Amiodarone: HRV 9.15 948 13,543 3,520 50,286
0% discount rate
No amiodarone 13.95
Amiodarone: HRV1EPS 13.98 402 ED 1,728 ED
Amiodarone: HRV 14.05 970 9,700 3,591 35,910
Results unadjusted for QOL
No amiodarone 10.65
Amiodarone: HRV1EPS 10.68 399 ED 1,717 ED
Amiodarone: HRV 10.74 957 10,633 3,548 39,422
C/E 5 cost-effectiveness; ED 5 dominated by extended dominance; LY 5 life-year; QALY 5 quality-adjusted life-year; QOL 5 quality of life; other abbreviations
as in Table 1.
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Figure 2. Incremental cost-effect-
iveness (C/E) ratios for the two
amiodarone strategies compared
with the noninterventional option,
using Italian costs (top) and Amer-
ican charges (bottom). Data con-
cerning base-case analysis as refer-
ence and alternative scenarios
tested in the sensitivity analysis
are shown. Solid bars show incre-
mental cost-effectiveness ratios of
amiodarone according to the com-
bined use of noninvasive testing
and electrophysiologic study (EPS);
open bars show incremental cost-
effectiveness ratios of amiodarone
according to noninvasive testing
only. When the strategy based on
noninvasive testing and electro-
physiologic study is dominated by
extended dominance, only the open
bar of the noninvasive strategy is
shown. HRV 5 heart rate variabil-
ity; LVEF 5 left ventricular ejec-
tion fraction; PVCs 5 premature
ventricular complexes; QALY 5
quality-adjusted life-year; SAECG 5
signal-averaged electrocardiogram;
us VT 5 unsustained ventricular
tachycardia.
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seems to be consistent with that of most currently accepted
programs. These findings should be taken into account in this
era of limited health care resources.
Amiodarone after acute myocardial infarction: which diag-
nostic tests should be used to select patients suitable for
long-term treatment? Results from the CAMIAT (7) and
EMIAT trials (8) showed that amiodarone does not reduce
total or cardiac mortality in postinfarction patients with fre-
quent premature ventricular complexes or left ventricular
dysfunction. However, arrhythmic mortality was significantly
reduced in both trials, suggesting a potential role for the drug
in patients at high risk for life-threatening ventricular arrhyth-
mias for whom amiodarone could offer a substantial survival
benefit (7,8).
It is currently extremely difficult to identify with a high
predictive accuracy the postinfarction patients who are at high
risk for an arrhythmic event and who might benefit from a
prophylactic treatment such as amiodarone. Among noninva-
sive risk markers, depressed heart rate variability was an
independent predictor of arrhythmic death, both in patients
with either a low or a normal ejection fraction (9). Inducibility
of sustained monomorphic ventricular tachycardia at electro-
physiologic study has proved to be the single best predictor of
spontaneous ventricular tachycardia and sudden death after
myocardial infarction (26). The key advantage of stratifying
patients after infarction by programmed stimulation versus less
invasive methods is that it may identify a small subgroup at
sufficient high risk of electrical events to justify prophylactic
antiarrhythmic intervention. Moreover, as previously described
in a group of patients preselected by the presence of noninva-
sive risk factors (10,11), programmed ventricular stimulation is
useful in improving diagnostic accuracy. As the first step,
noninvasive tests can be effectively used to limit the number of
postinfarction patients undergoing an electrophysiologic test.
As a second step, electrophysiologic study minimizes false
positive results because of its high negative predictive value.
This feature is of great relevance when the therapy given to
patients positive results is associated with both potential
toxicity and high costs, such is the case with amiodarone.
Patients without inducible arrhythmias, who have a good
prognosis despite the presence of different noninvasive mark-
ers, will be spared the risks of long-term treatment with
antiarrhythmic agents (10,11). From an economic point of
view, a reduction in the number of inappropriate treatments
after hospital discharge can save on health care resource use.
Cost-effectiveness of alternative diagnostic strategies in
arrhythmic risk stratification after acute myocardial infarc-
tion. Cost-effectiveness analysis allows a comparison of costs
of different strategies that achieve the same effect and may
facilitate choices between alternatives. Results of base-case
analysis showed that amiodarone therapy, when given to all
patients at risk after heart rate variability assessment, was the
most expensive of the regimens studied. Specifically, amioda-
rone therapy according to a combined use of heart rate
variability analysis and electrophysiologic testing resulted in
costs that were 58% and 52% lower, using Italian costs and
American charges, respectively. However, compared with the
no-therapy option, the gain in quality-adjusted life expectancy
was small. Therefore, the strategy based on amiodarone in
patients with both low heart rate variability and a positive
result on electrophysiologic testing was dominated by a blend
of the two alternatives. If amiodarone is given to prevent
arrhythmic death after myocardial infarction, selection of
patients according to heart rate variability analysis is a suffi-
ciently cost-effective approach. Goldman et al. (27) suggested
that an incremental cost-effectiveness ratio ,$20,000/
additional QALY is very attractive. Incremental cost-
effectiveness ratios between $20,000 and ;$40,000/QALY
gained are consistent with other currently founded programs,
such as hemodialysis or treatment of mild hypertension with
diuretic drugs or propranolol. Incremental cost-effectiveness
ratios between $60,000 and $100,000/additional QALY are
clearly higher than most currently accepted programs, whereas
ratios .$100,000 are generally agreed to be unattractive. With
reference to American charges, the present investigation
showed that amiodarone therapy in postinfarction patients at
high risk for arrhythmic death because of low heart rate
variability at 24-h Holter monitoring had an incremental
cost-effectiveness ratio of $39,422/QALY gained, which was
consistent with that of other commonly accepted health pro-
grams. Different discount rates as well as adjustment for
quality of life did not significantly change results.
We tested sensitivity to changes of those variables that may
be relevant as determinants of cost-effectiveness in the model.
With regard to amiodarone effectiveness, we performed two
additional analyses according to data reported in the CAMIAT
(7) and EMIAT (8) trials. Changes in arrhythmic, nonarrhyth-
mic cardiac and noncardiac death ranged from 233% to
245%, from 227% to 130% and from 0% to 137%, respec-
tively. In the CAMIAT scenario, results were not significantly
different from those reported in the base-case analysis. Ac-
cording to the model data from the EMIAT trial, no strategy
was clearly dominated by any other, and no strategy was
eliminated by extended dominance. However, by American
charges, the incremental cost-effectiveness ratios for both
alternative therapeutic strategies were higher than most cur-
rently accepted programs, ranging from $60,000 to $100,000/
additional QALY gained.
We also tested the model using costs based on monitoring
in the CAMIAT (7) and EMIAT (8) trials. Validity of the
model was still supported by concordance of the results with
those observed in the baseline analysis, suggesting that study
results were independent of the adopted monitoring program.
Different combinations of noninvasive risk markers (i.e.,
left ventricular ejection fraction, premature ventricular com-
plexes, unsustained ventricular tachycardia and ventricular late
potentials) were introduced into the model. The results did not
support the use of an additional electrophysiologic study if the
first-level screening was based on abnormalities of two nonin-
vasive tests. Conversely, data suggest the use of programmed
stimulation in those patients with only one positive marker
among low ejection fraction, late potentials and unsustained
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ventricular tachycardia. Nevertheless, despite a similar cost-
effectiveness ratio, the increase in quality-adjusted life expect-
ancy induced by amiodarone in patients with low heart rate
variability was 125% to 200% higher. This finding seems to
agree with recent data from a prospective substudy of the
EMIAT trial (28) that suggests a potential role for heart rate
variability as the best noninvasive test for screening postinfarc-
tion patients who may benefit from amiodarone therapy.
Finally, we changed the model with regard to probability of
cardiac death in patients with positive and negative results on
the electrophysiologic study. After exclusion of data from
Bourke et al. (15), new estimates were calculated. When a
programmed ventricular stimulation sensitivity for cardiac
arrhythmic and nonarrhythmic death of 78% and 20%, respec-
tively, and a specificity of 80% (10,11,16) were assumed, the
results were found to be sensitive, and no strategy was clearly
dominated by any other. Using American charges,
electrophysiologic-guided amiodarone strategy had a very at-
tractive incremental cost-effectiveness ratio of $21,150/QALY
gained. Nevertheless, overall examination of sensitivity analysis
showed that results were robust, and the model results had
only slight changes compared with baseline assumptions.
Conclusions. The present investigation was designed to
estimate the cost-effectiveness of amiodarone therapy in postin-
farction patients at high risk for arrhythmic death. The influ-
ence of alternative diagnostic strategies on amiodarone-
induced survival benefit and the cost-effectiveness ratio was
also evaluated. The results do not support the use of an
electrophysiologic study after heart rate variability analysis for
selecting candidates for long-term amiodarone therapy. More-
over, the cost-effectiveness ratio of amiodarone therapy in
patients with depressed heart rate variability after myocardial
infarction seems to be consistent with that of most currently
accepted health care programs. These findings might be im-
portant in the allocation of limited health care resources.
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